PTC News - Candlesense

RareMed Announces Expansion of Relationship with PTC Therapeutics

(NASDAQ:PTC) PITTSBURGH, Sept. 2, 2025 /PRNewswire/ -- RareMed Solutions®, the nation's leader in patient support services for complex therapies, is proud to announce an expansion of its relationsh...

Partnerships

13 days ago

European Commission Grants Approval of OGSIVEO® (nirogacestat) for the Treatment of Adults with Desmoid Tumors

OGSIVEO is the first and only therapy to receive marketing authorization in the EU for the treatment of desmoid tumors OGSIVEO is the first and only therapy to receive marketing authorization in t...

What regulatory, pricing, or reimbursement hurdles could affect OGSIVEO's rollout in other regions and its long‑term growth trajectory? What is the expected EU market size and revenue contribution from OGSIVEO, and how does it compare to existing treatments and competitors? How will the EU approval of OGSIVEO impact PTC's short‑term stock price and trading volume?

Drug approval

28 days ago

PTC Appoints Jon Stevenson as Executive Vice President, Chief Product Officer

BOSTON, Aug. 11, 2025 /PRNewswire/ -- PTC (NASDAQ: PTC) today announced that it has appointed Jon Stevenson as Executive Vice President, Chief Product Officer. Stevenson will be responsible for the...

How might this appointment affect analyst sentiment and future earnings estimates for PTC? What are the potential risks or uncertainties associated with the transition period for the Digital Thread product line? Could the new leadership lead to accelerated partnerships or acquisitions that might influence PTC's valuation?

Leadership

about 1 month ago